Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allya
- Development stage
- Discontinued
- Lead developer
- University of Southampton
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Allya is a branded botanical formulation of Devil's Claw (*Harpagophytum procumbens*), a plant native to Southern Africa traditionally used for its anti-inflammatory and analgesic properties. Developed and evaluated in clinical trials by the University of Southampton, Allya is specifically targeted for the treatment of pain and stiffness associated with osteoarthritis of the knee and hip. The extract's primary bioactive constituent is harpagoside, an iridoid glycoside that inhibits inflammatory pathways, including the cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) enzymes. As a phytotherapeutic product, it is positioned as a potentially safer alternative to conventional non-steroidal anti-inflammatory drugs (NSAIDs), which are often limited by gastrointestinal side effects during long-term use.
- Brand names
- Allya
- Other names
- Devil's ClawHarpagophytum procumbens extract
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)NF-κBNOS2 (Nitric Oxide Synthase 2)
Beyond the preview
Go deeper on Allya.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allya.